NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) — IO Biotech IOBT, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced today that biopharma executive Christine Richter joined the company as SVP, Commercial and Program Lead for IO102-IO103, the company’s lead cancer vaccine candidate.…Read More
IO Biotech Appoints Christine Richter PhD MBA as Senior Vice President Commercial and Program Lead IO Biotech NASDAQIOBT
